STOCK TITAN

[Form 4] PAVmed Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Michael J. Glennon, a director of PAVmed Inc. (PAVM), was granted 150,000 restricted shares on 09/30/2025 under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan at a reported price of $0. After the grant his total beneficial ownership is reported as 231,667 shares. The restricted shares vest on May 20, 2028 and are subject to forfeiture if the required service period is not completed. The Form 4 was signed by power of attorney on 10/02/2025.

Michael J. Glennon, un direttore di PAVmed Inc. (PAVM), ha ricevuto 150.000 azioni soggette a restrizioni il 30/09/2025 ai sensi del Sesto Piano di Incentivazione Azionaria a Lungo Termine del 2014, come emendato e riscritto dell’emittente ad un prezzo riportato di $0. Dopo l’assegnazione la sua proprietà beneficiaria totale è riportata come 231.667 azioni. Le azioni soggette a restrizioni maturano il 20/05/2028 e sono soggette a perdita se non viene completato il periodo di servizio richiesto. Il Form 4 è stato firmato per procura il 02/10/2025.

Michael J. Glennon, un director de PAVmed Inc. (PAVM), recibió 150.000 acciones restringidas el 30/09/2025 bajo el Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan del emisor a un precio reportado de $0. Después de la concesión su propiedad beneficiosa total se reporta como 231,667 acciones. Las acciones restringidas vencen el 20/05/2028 y están sujetas a la pérdida si no se completa el periodo de servicio requerido. El Form 4 fue firmado por poder el 02/10/2025.

Michael J. Glennon, PAVmed Inc. (PAVM)의 이사로서, 발행사의 2014년 장기 주식 인센티브 계획 제6차 개정 및 재작성에 따라 2025-09-30150,000주의 제한 주식을 $0의 보고 가격으로 수여받았습니다. 수여 후 그의 총 유익한 소유는 231,667주로 보고됩니다. 제한 주식은 2028-05-20에 vesting되며 필요한 서비스 기간을 완료하지 않으면 몰수될 수 있습니다. Form 4는 2025-10-02에 위임장으로 서명되었습니다.

Michael J. Glennon, directeur de PAVmed Inc. (PAVM), a reçu 150 000 actions restreintes le 30/09/2025 dans le cadre du Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan de l’émetteur à un prix déclaré de $0. Après l’octroi, sa propriété bénéficiaire totale est déclarée à 231 667 actions. Les actions restreintes se vistent le 20/05/2028 et sont susceptibles d’être perdues si la période de service requise n’est pas accomplie. Le Form 4 a été signé par procuration le 02/10/2025.

Michael J. Glennon, ein Direktor von PAVmed Inc. (PAVM), erhielt 150.000 eingeschränkte Aktien am 30.09.2025 im Rahmen des Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan des Emittenten zu einem gemeldeten Preis von $0. Nach der Gewährung wird sein gesamter wirtschaftlicher Anteil als 231.667 Aktien gemeldet. Die eingeschränkten Aktien vesten am 20.05.2028 und können verfallen, wenn die erforderliche Dienstzeit nicht erfüllt wird. Das Form 4 wurde am 02.10.2025 durch Vollmacht unterzeichnet.

مايكل ج. جلينون، مدير في PAVmed Inc. (PAVM)، مُنح 150,000 سهماً مقيداً في 30/09/2025 بموجب خطة الأسهم التحفيزية طويلة الأجل لعام 2014 المعدلة سادساً الخاصة بالمرسل، بسعر مُبلغ عنه قدره $0. بعد المنحة تُبلَّغ ملكيته المفيدة الإجمالية كـ 231,667 سهماً. تتفكَّك الأسهم المقيدة في 20/05/2028 وتكون قابلة للسقوط إذا لم يتم إكمال فترة الخدمة المطلوبة. تم توقيع النموذج 4 بالنيابة عن طريق توكيل في 02/10/2025.

迈克尔 J. Glennon,PAVmed Inc.(PAVM)的董事,在发行方的2014 年度长期股权激励计划第六次修订及重述下于2025-09-30获授150,000股受限股票,报价为$0。授予后,他的总受益所有权为231,667股。受限股票将于2028-05-20生效,如未完成所需的服务期限,可能被没收。Form 4 已于2025-10-02由授权书签署。

Positive
  • 150,000 restricted shares granted to a director, increasing alignment with shareholders
  • Reporting person’s total beneficial ownership increased to 231,667 shares
  • Grant issued under the company’s Sixth Amended and Restated 2014 Long‑Term Incentive Equity Plan
Negative
  • Restricted shares have a single vesting date of May 20, 2028, delaying liquidity and economic alignment
  • Grants are subject to forfeiture if service period is not completed, which could reverse ownership if the director departs

Insights

Director received time‑based equity that vests in 2028.

The reporting shows a 150,000 restricted stock grant to Michael J. Glennon on 09/30/2025 under the company’s 2014 Long‑Term Incentive Equity Plan. The grant was recorded at $0 and increases his beneficial ownership to 231,667 shares.

The award is time‑based with a single vesting date of May 20, 2028 and is forfeitable if service requirements are not met, aligning director incentives with long‑term tenure but delaying potential economic benefit.

Michael J. Glennon, un direttore di PAVmed Inc. (PAVM), ha ricevuto 150.000 azioni soggette a restrizioni il 30/09/2025 ai sensi del Sesto Piano di Incentivazione Azionaria a Lungo Termine del 2014, come emendato e riscritto dell’emittente ad un prezzo riportato di $0. Dopo l’assegnazione la sua proprietà beneficiaria totale è riportata come 231.667 azioni. Le azioni soggette a restrizioni maturano il 20/05/2028 e sono soggette a perdita se non viene completato il periodo di servizio richiesto. Il Form 4 è stato firmato per procura il 02/10/2025.

Michael J. Glennon, un director de PAVmed Inc. (PAVM), recibió 150.000 acciones restringidas el 30/09/2025 bajo el Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan del emisor a un precio reportado de $0. Después de la concesión su propiedad beneficiosa total se reporta como 231,667 acciones. Las acciones restringidas vencen el 20/05/2028 y están sujetas a la pérdida si no se completa el periodo de servicio requerido. El Form 4 fue firmado por poder el 02/10/2025.

Michael J. Glennon, PAVmed Inc. (PAVM)의 이사로서, 발행사의 2014년 장기 주식 인센티브 계획 제6차 개정 및 재작성에 따라 2025-09-30150,000주의 제한 주식을 $0의 보고 가격으로 수여받았습니다. 수여 후 그의 총 유익한 소유는 231,667주로 보고됩니다. 제한 주식은 2028-05-20에 vesting되며 필요한 서비스 기간을 완료하지 않으면 몰수될 수 있습니다. Form 4는 2025-10-02에 위임장으로 서명되었습니다.

Michael J. Glennon, directeur de PAVmed Inc. (PAVM), a reçu 150 000 actions restreintes le 30/09/2025 dans le cadre du Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan de l’émetteur à un prix déclaré de $0. Après l’octroi, sa propriété bénéficiaire totale est déclarée à 231 667 actions. Les actions restreintes se vistent le 20/05/2028 et sont susceptibles d’être perdues si la période de service requise n’est pas accomplie. Le Form 4 a été signé par procuration le 02/10/2025.

Michael J. Glennon, ein Direktor von PAVmed Inc. (PAVM), erhielt 150.000 eingeschränkte Aktien am 30.09.2025 im Rahmen des Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan des Emittenten zu einem gemeldeten Preis von $0. Nach der Gewährung wird sein gesamter wirtschaftlicher Anteil als 231.667 Aktien gemeldet. Die eingeschränkten Aktien vesten am 20.05.2028 und können verfallen, wenn die erforderliche Dienstzeit nicht erfüllt wird. Das Form 4 wurde am 02.10.2025 durch Vollmacht unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Glennon Michael J

(Last) (First) (Middle)
360 MADISON AVENUE
25TH FLOOR

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 09/30/2025 A 150,000(1) A $0(1) 231,667 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
/s/ Michael A. Gordon, by power of attorney 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for PAVmed (PAVM)?

The Form 4 reports transactions by Michael J. Glennon, a director of PAVmed Inc.

What security did the reporting person acquire in the Form 4?

The filing shows a grant of 150,000 restricted shares of PAVmed common stock on 09/30/2025.

How many shares does the reporting person beneficially own after the grant?

Following the reported transaction, the reporting person beneficially owns 231,667 shares.

When do the restricted shares vest?

The restricted shares vest on a single date: May 20, 2028, and are subject to forfeiture if service is not completed.

Under what plan were the restricted shares granted?

The shares were granted under the issuer’s Sixth Amended and Restated 2014 Long‑Term Incentive Equity Plan.
Pavmed

NASDAQ:PAVM

PAVM Rankings

PAVM Latest News

PAVM Latest SEC Filings

PAVM Stock Data

9.55M
18.02M
18.43%
10.64%
1.15%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK